NTLA 10-Q report for 2026-03-31

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments.

This Form 10‑Q contains Intellia’s unaudited condensed consolidated financial statements and MD&A for the quarter ended March 31, 2026. Key reported items: cash and cash equivalents of $134.7M, total current assets of $466.4M, total assets of $758.8M, total liabilities of $137.8M, and total stockholders’ equity of $620.9M as of March 31, 2026. For the three months ended March 31, 2026 the company reported collaboration revenue of $15.0M, R&D expense of $80.7M, G&A expense of $34.8M, total operating expenses of $115.6M and a net loss of $96.2M (net loss per share $0.81). Operating cash used was $117.3M for the quarter. The notes describe Intellia’s lead in vivo CRISPR candidates (lonvo‑z and nex‑z) and state that the company reported positive topline Phase 3 HAELO results for lonvo‑z in April 2026, with preparations underway for a planned commercial launch in H1 2027. The filing confirms that cash, cash equivalents and marketable securities as of March 31, 2026 are expected to fund operations for at least the next twelve months. This 10‑Q is primarily a financial and disclosure update—actionability centers on reassessing capital runway, R&D burn and dilution risk; the recommended strategy is to sell.

This excerpt is only the cover page/header of Sleep Number’s Form 10-Q for the quarter ended April 4, 2026. It contains filing metadata (issuer, ticker, exchange, address) but no financial statements, MD&A, guidance, risks, or operational commentary. As a result, it is not directly actionable for trading beyond confirming the filing exists.

The provided excerpt is only the cover/filing header of SoundHound AI, Inc.’s 10‑Q for the quarter ended 2026‑03‑31. It contains listing/security identifiers (SOUN, SOUNW) but no financial statements, MD&A, guidance, risk updates, liquidity details, or material events. As a result, there is insufficient information to form high-confidence, actionable bullish/bearish theses beyond generic “company filed its 10‑Q” metadata.

The provided excerpt is only the boilerplate cover/filing-status section of Teucrium Commodity Trust’s Form 10‑Q for period ended 2026‑03‑31, with no portfolio holdings, performance, risk, or material updates included. As-is, it contains no actionable investment information beyond confirming the existence of the filing and the issuer/ticker identity (WEAT).

This excerpt is only the cover page of Archer Aviation’s Form 10‑Q for the quarter ended 2026‑03‑31 (issuer identity, exchange listing, and securities outstanding). It contains no operating/financial results, guidance, liquidity details, backlog, or risk-factor updates—so it is minimally actionable for trading beyond basic security identifiers and a generic dilution/optionality consideration from warrants.

This excerpt is essentially the cover page of CleanSpark, Inc.’s Form 10-Q for the quarter ended March 31, 2026. It contains identifiers (CIK/file no.), listing venue, and security descriptions (common stock and redeemable warrants with specific exercise terms), but no operating/financial results, guidance, risks, or MD&A detail. Actionability is therefore limited to capital-structure/dilution considerations around the listed warrant.

This excerpt of AST SpaceMobile’s 10‑Q is largely SEC cover-page/boilerplate (registrant info, exchange listing, filing compliance) and contains no financial results, guidance, liquidity, risk-factor updates, or operating metrics. As provided, it does not create a clear tradable catalyst beyond confirming continued reporting/listing status.

This excerpt only includes the cover page of Super Micro Computer, Inc.’s Form 10‑Q for the quarter ended March 31, 2026. It confirms the filing, issuer identity, listing (Nasdaq), and ticker (SMCI), but contains no financial results, guidance, risks, or MD&A content to support a directional investment view.

The provided text is only the cover/header portion of AbCellera Biologics Inc.’s Form 10‑Q for the quarter ended March 31, 2026 (identifying info, exchange listing, filing status). It contains no financial statements, guidance, risk updates, material events, MD&A, cash runway, pipeline/program updates, or disclosures that would support a differentiated trading view.